Priyanka Iyer, M.B.B.S
Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Program Director, Oncologic Endocrinology Fellowship Program, Endocrine Neoplasia & Hormonal Disorder, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2009 | Armed Forces Medical College, Pune Maharashtra University of Health Sciences, Pune, IN, Medicine, MBBS |
Postgraduate Training
| 2017-2018 | Research Fellowship, Endocrinology, Diabetes and Metabolism, Baylor College of Medicine/The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2015-2017 | Clinical Fellowship, Endocrinology, Diabetes and Metabolism, Baylor College of Medicine/The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2014-2015 | Chief Resident, Internal Medicine, Johns Hopkins University/Sinai Hospital Program, Baltimore, Maryland |
| 2012-2014 | Clinical Residency, Internal Medicine, Johns Hopkins University/Sinai Hospital Program, Baltimore, Maryland |
| 2011-2012 | Clinical Internship, Internal Medicine, Johns Hopkins University/Sinai Hospital Program, Baltimore, Maryland |
Licenses & Certifications
| 2025 | Basic Life Support |
| 2023 | DEA License |
| 2022 | Texas Medical Board License |
| 2018 | Oregon Medical License |
| 2017 | American Board of Internal Medicine - Endocrinology, Diabetes and Metabolism |
| 2014 | American Board of Internal Medicine |
| null | Louisiana State Board of Medical Examiners License |
| null | Alabama Board of Medical Examiners License |
| null | Washington State Department of Health License |
| null | Tennessee Board of Medical Examiners License |
| null | Arizona Board of Medical Examiners License |
| null | Oklahoma State Board of Medical License |
| null | Mississippi State Board of Medical Licensure |
| null | Georgia Composite Medical Board |
| null | Florida Board of Medicine |
Experience & Service
Faculty Academic Appointments
Associate Program Director, Oncologic Endocrinology Fellowship Program, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - 2026
Other Professional Positions
Affiliate Clinical Assistant Professor, Texas A&M Vashisht College of Medicine, 2026 - 2029
Endocrinologist, PeaceHealth Medical Group, Eugene, OR, 2018 - 2022
Extramural Institutional Committee Activities
Member, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Scientific Review Review Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, IOTOX Working group Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Oncologic Fellowship Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Anaplastic Thyroid Cancer (ATC) Planning Clinic, The University of Texas MD Anderson Cancer Center, 2016 - Present
Honors & Awards
| 2018 | Helmsley Charitable Trust Abstract Awards in Type 1 Diabetes, Endocrine Society |
| 2018 | Young Investigator Award, Women in Endocrinology, Endocrine Society |
| 2018 | First Prize, Clinical Research poster session, Division of Internal Medicine Research Retreat, The University of Texas MD Anderson Cancer Center |
| 2018 | First Prize, Clinical Research poster session, Research Symposium,, Baylor College of Medicine |
| 2017 | Finalist, DOIM Research Retreat Poster Session, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center |
| 2017 | First Prize, Trainee Poster Contest in the Clinical Research Category, American Thyroid Association (ATA) |
| 2017 | Dr. Lawrence CB Chan Award for Research Excellence, Baylor College of Medicine |
| 2016 | The Leona M. and Harry B. Helmsley Charitable Trust Abstract Travel Support Award, Endocrine Society |
| 2014 | Finalist (Second Place), Maryland ACP Diagnostic Dilemma Competition |
| 2011 - 2014 | Outstanding Performance Award in the Area of Ambulatory Medicine, Sinai Hospital |
| 2011 - 2013 | Excellence in Professionalism and Humanism Award, Sinai Hospital |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Advanced Thyroid Cancer- Thinking Outside the Box!. Invited. ThyCa. Houston, Texas, US.
- 2024. ABCs of Thyroid cancer, Advanced Thyroid Cancer. Invited. ThyCa. Houston, Texas, US.
- 2023. ABCs of Thyroid Cancer. Invited. ThyCa. Houston, Texas, US.
- 2022. IOTOX Endocrine Toxicities. Invited. National IOTOX Clinical Educational symposium. Houston, TX, US.
- 2017. Molecular targeted therapy in anaplastic thyroid carcinoma. Conference. Molecular targeted therapy in anaplastic thyroid carcinoma. Houston, TX, US.
Regional Presentations
- 2025. Navigating Complex Cases of Thyroid Cancer. Invited. Texas Endocrinology Association (TXEA). San Antonio, Texas, US.
National Presentations
- 2026. Session Leader:. 29th International Thyroid Cancer Survivors’ Conference. Cary (Raleigh), North Carolina.
- 2026. Lecture: Management of Radioiodine refractory Thyroid Cancer. Invited. AACE.
- 2025. Lecture: Advanced Thyroid Cancer Case Based Learning. AACE.
- 2018. Checkpoint Inhibitor Mediated Insulin Dependent Diabetes: A Cancer Center Experience. Conference. Checkpoint Inhibitor Mediated Insulin Dependent Diabetes: A Cancer Center Experience. Chicago, IL, US.
- 2016. Immunotherapy-related destructive thyroiditis: A Cancer Center Experience. Conference. Immunotherapy-related destructive thyroiditis: A Cancer Center Experience. Denver, CO, US.
International Presentations
- 2026. Multidisciplinary Treatment of Anaplastic Thyroid Cancer. Invited. AACE. Mumbai, IN.
- 2025. Changing Landscape of Management of Anaplastic Thyroid Cancer. Invited. Alberta, CA.
- 2024. GRASSROOT- Global Real-world data in patients with Advanced thyroid cancer on Standard of care and Specialized Interventions- Registry of Oncologic Outcomes with Testing and treatment. Poster. ESMO Asia Congress 2024, SG.
- 2023. Management of Anaplastic Thyroid Cancer. Invited, PH.
Formal Peers
- 2023. FY23 IOTOX Educational Lecture Series. Visiting, US.
- 2023. Management of Anaplastic Thyroid Carcinoma. Visiting, US.
- 2022. FY23 IOTOX Educational Lecture Series. Visiting, US.
- 2022. Grand Rounds. Visiting, US.
Grant & Contract Support
| Date: | 2025 - Present |
| Title: | Phase 1, FIH, open-label, nonrandomized, multicenter study of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway |
| Funding Source: | Jazz Pharmaceuticals |
| Role: | Co-I |
| Date: | 2025 - Present |
| Title: | Checkpoint inhibitor associated diabetes mellitus: early recognition and treatment (CERT) project: a pilot study |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2025 - Present |
| Title: | A Phase 2 Master Protocol To Assess The Efficacy And Safety Of FORE8394, An Inhibitor Of BRAF Class 1 And Class 2 Alterations, In Participants With Cancer Harboring BRAF Alterations |
| Funding Source: | Fore Biotherapeutics US |
| Role: | Co-I |
| Date: | 2024 - Present |
| Title: | GRASSROOT clinical trial- Master Observational |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2024 - Present |
| Title: | ZAnzalintinib Neoadjuvant EValuation In Thyroid Oncology (ZANEVO) |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| Date: | 2024 - Present |
| Title: | Global Real world data in patients with Advanced thyroid cancer on Standard of care and Specialized interventions- Registry of Oncologic Outcomes with Testing and treatment |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2023 - Present |
| Title: | A phase I trial of concurrent intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF mutated anaplastic or poorly differentiated Thyroid Cancer |
| Funding Source: | City of Hope |
| Role: | Co-I |
| Date: | 2023 - Present |
| Title: | Targeted therapy to increase RAI uptake in patients with metastatic differentiated thyroid Cancer |
| Funding Source: | The Children's Hospital of Philadephia |
| Role: | Co-I |
| Date: | 2021 - Present |
| Title: | A Phase 2 Study of Neoadjuvant Lenvatinib in Locally Advanced Invasive Thyroid Cancer |
| Funding Source: | Massachusetts Eye and Ear Infirmary |
| Role: | Co-I |
Selected Publications
Book Chapters
- Abdallah D, Iyer PC, Chahla B, Habra MA. Endocrine Malignancies. In: The MD Anderson Manual of Medical Oncology. Fifth. McGraw Hill, 2027.
- Iyer, PC, Srour, S, Hofmann, M, Cabanillas, ME. Current Trends in Treatment and New Generation of Trials in Thyroid Cancer, 307-324, 2024.
- Iyer PC, Abadilla K, Dobs A. Medical disorders and complications of alcohol and other drugs, pain and addiction. In: Textbook of Addiction Treatment: International Perspectives. Springer Milan Heidelberg New York Dordrecht London, 1811-1830, 2015.
Patient Reviews
CV information above last modified September 08, 2026